Assessment of The Risk Factors for Statin-Related Myopathy in the Indian Population
Pharmaceutical Science-Pharma
DOI:
https://doi.org/10.22376/ijlpr.2023.13.3.P70-P75Keywords:
Statin-induced myopathy, atorvastatin, statin risks, smoking.Abstract
Statins are widely used hypolipidemic drugs with limitations due to myopathy. Several comorbid factors act as predisposing factors for statin-related myopathy (SRM) and are rarely studied in the Indian population. In this study, we aim to understand the various risk factors involved in the occurrence of SRM, which may give insight towards the management of statin intolerance. A cross-sectional and non-interventional clinical study with 700 subjects, both statin and non-statin users, was conducted. Subjects were enrolled after ethical approval and informed consent. Information on case report forms and blood samples for clinical chemistry investigations were collected. SPSS version 21 was used to collect and analyze data. Based on statistical analysis, we found myopathy in statin users (19%), nonstatin users (11%), and total subjects (16%), respectively. No significant association of myopathy was observed with the female sex, differences in food habits, physical activity, alcohol intake, or comorbid factors like diabetes and hypertension. Smoking is associated with myopathy in pooled subjects, whereas age (>60) is associated with myopathy in statin users. Slight differences in mean values of bilirubin and alanine transferase were observed between myopathic and non-myopathic subjects. Therefore, the study demonstrates that smoking is related to myopathy regardless of statin usage. Statin users over 60 were shown to be at a greater risk for myopathy than non-statin users.
References
Sathasivam S, Lecky B. Statin-induced myopathy. BMJ. 2008;337: a2286. doi: 10.1136/bmj.a2286, PMID 18988647.
Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185-90. doi: 10.1002/mus.21486, PMID 19813188.
Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014 Oct;96(4):470-6. doi: 10.1038/clpt.2014.121, PMID 24897241.
Echaniz-Laguna A, Mohr M, Lannes B, Tranchant C. Myopathies in the elderly: a hospital-based study. Neuromuscul Disord. 2010 Jul;20(7):443-7. doi: 10.1016/j.nmd.2010.05.003, PMID 20621722.
Zhu Y, Chiang CW, Wang L, Brock G, Milks MW, Cao W et al. A multistate transition model for statin-induced myopathy and statin discontinuation. CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1236-44. doi: 10.1002/psp4.12691, PMID 34562311.
Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2(5):205-7. doi: 10.1186/cm-2-5-205, PMID 11806796.
Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis. 2009 Jan;202(1):18-28. doi: 10.1016/j.atherosclerosis.2008.05.021, PMID 18585718.
Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006 Dec 19;114(25):2788-97. doi: 10.1161/Circulationaha.106.624890, PMID 17159064.
Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011 May;10(3):373-87. doi: 10.1517/14740338.2011.540568, PMID 21342078.
Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16(3):352-8. doi: 10.1002/pds.1287, PMID 16892458.
Munshi SK, Thanvi B, Jonnalagadda SJ, Da Forno P, Patel A, Sharma S. Inclusion body myositis: an underdiagnosed myopathy of older people. Age Ageing. 2006 Jan;35(1):91-4. doi: 10.1093/ageing/afj014, PMID 16364943.
Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007;49(17):1753-62. doi: 10.1016/j.jacc.2007.01.067, PMID 17466224.
Simon L, Jolley SE, Molina PE. Alcoholic myopathy: pathophysiologic mechanisms and clinical implications. Alcohol Res. 2017;38(2):207-17. PMID 28988574.
Degens H, Gayan-Ramirez G, van Hees HW. Smoking-induced skeletal muscle dysfunction: from evidence to mechanisms. Am J Respir Crit Care Med. 2015 Mar 15;191(6):620-5. doi: 10.1164/rccm.201410-1830PP, PMID 25581779.
Phillips BA, Mastaglia FL. Exercise therapy in patients with myopathy. Curr Opin Neurol. 2000 Oct;13(5):547-52. doi: 10.1097/00019052-200010000-00007, PMID 11073361.
Chung HR, Vakil M, Munroe M, Parikh A, Meador BM, Wu PT et al. The impact of exercise on statin-associated skeletal muscle myopathy. PLOS ONE. 2016 Dec 9;11(12):e0168065. doi: 10.1371/journal.pone.0168065, PMID 27936249.
Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N et al. Low serum 25 (OH) vitamin D levels (<32 ng/ml) are associated with reversible myositis‐myalgia in statin‐treated patients. Transl Res. 2009;153(1):11-6. doi: 10.1016/j.trsl.2008.11.002, PMID 19100953.
Abed W, Abujbara M, Batieha A, Ajlouni K. Statin Induced myopathy among Patients Attending the National Center for Diabetes, Endocrinology, & Genetics. Ann Med Surg (Lond). 2022 Jan 27;74:103304. doi: 10.1016/j.amsu.2022.103304, PMID 35145672.
Riche KD, Arnall J, Rieser K, East HE, Riche DM. Impact of vitamin D status on statin-induced myopathy. J Clin Transl Endocrinol. 2016 Nov 23;6:56-9. doi: 10.1016/j.jcte.2016.11.002, PMID 29067242.
Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair. 2005 Sep;19(3):259-63. doi: 10.1177/1545968305277167, PMID 16093417.
Aksnes L. A simplified high-performance liquid chromatographic method for determination of vitamin D3, 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in human serum. Scand J Clin Lab Invest. 1992 May;52(3):177-82. doi: 10.3109/00365519209088782, PMID 1329183.
Lowe K, Kubra KT, He ZY, Carey K. Vitamin D supplementation to treat statin-associated muscle symptoms: a review. SR Care Pharm. 2019 Apr 1;34(4):253-7. doi: 10.4140/TCP.n.2019.253, PMID 30935447.
Laniado-Laborín R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. Int J Environ Res Public Health. 2009 Jan;6(1):209-24. doi: 10.3390/ijerph6010209, PMID 19440278.
Manoj K, Jain N, Madhu SV. Myopathy in patients taking atorvastatin: A pilot study. Indian J Endocrinol Metab. 2017 Jul-Aug;21(4):504-9. doi: 10.4103/ijem.IJEM_79_17, PMID 28670530.
Volpi E, Nazemi R, Fujita S. Muscle tissue changes with ageing. Curr Opin Clin Nutr Metab Care. 2004 Jul;7(4):405-10. doi: 10.1097/01.mco.0000134362.76653.b2, PMID 15192443.
Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging. 2013;8:47-59. doi: 10.2147/CIA.S29686, PMID 23355775.
Riche KD, Arnall J, Rieser K, East HE, Riche DM. Impact of vitamin D status on statin-induced myopathy. J Clin Transl Endocrinol. 2016 Nov 23;6:56-9. doi: 10.1016/j.jcte.2016.11.002, PMID 29067242.
Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. Gastroenterol Hepatol (N Y). 2013 Sep;9(9):605-6. PMID 24729773.
Nogueira AA, Strunz CM, Takada JY, Mansur AP. Biochemical markers of muscle damage and high serum concentration of creatine kinase in patients on statin therapy. Biomark Med. 2019 Jun;13(8):619-26. doi: 10.2217/bmm-2018-0379, PMID 31157560.
Published
How to Cite
Issue
Section
Copyright (c) 2023 A. Kiranmayee, R.Shyam Sunder, Dr.B.Dinesh Kumar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
